AIM2 and prostate carcinoma: AIM2, an interferon (IFN) inducible protein, is constitutively down-regulated in prostate cancer, however, IFN-induced AIM2 inflammasome activation leads to increased production of IL-1β and IL-18 in prostate cancer cell lines.